Astria Therapeutics, Inc. financial data

Symbol
ATXS on Nasdaq
Industry
Pharmaceutical Preparations
Location
22 Boston Wharf Road, 10 Th Floor, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
CATABASIS PHARMACEUTICALS INC (to 8/20/2021)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.44K % -7.76%
Debt-to-equity 4.89 % +23.5%
Return On Equity -30.8 % -15%
Return On Assets -29.4 % -13.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.4M shares +55.5%
Common Stock, Shares, Outstanding 56.4M shares +101%
Entity Public Float 280M USD +994%
Common Stock, Value, Issued 57K USD +104%
Weighted Average Number of Shares Outstanding, Basic 57.8M shares +106%
Weighted Average Number of Shares Outstanding, Diluted 57.8M shares +106%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 32.4M USD +40.2%
Operating Income (Loss) -116M USD -84%
Nonoperating Income (Expense) 16.1M USD +92.5%
Net Income (Loss) Attributable to Parent -100M USD -82.7%
Earnings Per Share, Basic -2.17 USD/shares -2.36%
Earnings Per Share, Diluted -2.17 USD/shares -2.36%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 80.9M USD -32.5%
Cash, Cash Equivalents, and Short-term Investments 344M USD +82.4%
Assets, Current 352M USD +83.8%
Operating Lease, Right-of-Use Asset 5.39M USD +949%
Other Assets, Noncurrent 4.39M USD +133%
Assets 362M USD +86.5%
Accounts Payable, Current 1.28M USD +12.3%
Employee-related Liabilities, Current 3.62M USD +35.4%
Accrued Liabilities, Current 13.1M USD +68.5%
Liabilities, Current 15.7M USD +67.6%
Operating Lease, Liability, Noncurrent 4.26M USD
Liabilities 20M USD +113%
Accumulated Other Comprehensive Income (Loss), Net of Tax 331K USD
Retained Earnings (Accumulated Deficit) -649M USD -18.2%
Stockholders' Equity Attributable to Parent 342M USD +85.2%
Liabilities and Equity 362M USD +86.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.1M USD -44.1%
Net Cash Provided by (Used in) Financing Activities 142M USD +283%
Net Cash Provided by (Used in) Investing Activities -126M USD -165%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 56.4M shares +101%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.52M USD -102%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 80.9M USD -32.6%
Deferred Tax Assets, Valuation Allowance 125M USD +20.4%
Deferred Tax Assets, Gross 125M USD +20.2%
Operating Lease, Liability 5.64M USD +1055%
Payments to Acquire Property, Plant, and Equipment 5K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -99.7M USD -82.9%
Lessee, Operating Lease, Liability, to be Paid 6.62M USD +1205%
Operating Lease, Liability, Current 1.38M USD +182%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.61M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.58M USD +299%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 978K USD +5047%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.64M USD
Deferred Tax Assets, Operating Loss Carryforwards 85.7M USD +6.99%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.53M USD
Operating Lease, Payments 1M USD +42.9%
Additional Paid in Capital 895M USD +40.2%
Deferred Tax Assets, Net of Valuation Allowance 99K USD -61.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%